Skip to content
Open access

[64/67Cu]-FAP theranostics in combination with immunotherapy in a preclinical model of TNBC

Sep 2026 · Research Square · 0 citations · 52 references
Medicine

TL;DR

The authors can noninvasively target and predict response to FAP radiolabeled with elementally paired theranostic probe, [64/67Cu]-FAP2287 in TNBC and can guide personalized approaches to improve treatment efficacy.

Abstract

Rationale: Fibroblast activation protein (FAP) is a prominent transmembrane protein in the tumor microenvironment (TME) that promotes tumorigenesis. FAP has been a recent target for radionuclide-conjugated peptides for PET imaging and targeted radionuclide therapy (TRT). The objective of this study is to develop a theranostic approach using [64/67Cu]-FAP2287 in combination with immunotherapy (IMT) to treat triple-negative breast cancer (TNBC). Methods 4T1 tumor-bearing BALB/c mice (N = 20) were injected and imaged with 100μCi [64Cu]-FAP2287 PET at 1, 4, and 24h to quantify baseline FAP expression followed by autoradiography. 4T1-tumor bearing BALB/c mice (N = 42) were divided into Control, IMT, 800μCi [67Cu]-FAP2287 or 4)[67Cu]-FAP2287 + IMT and 1600μCi [67Cu]-FAP2287, or [67Cu]-FAP2287 + IMT (N = 5–10/group) and imaged with [64Cu]-FAP2287 PET followed by treatment. All [67Cu]-FAP2287 groups were imaged with SPECT at 4, 24, and 48h. Tumor growth and survival rates were monitored. Standard uptake values (SUV) quantified, statistical analysis and probability of survival were done with significance at p < 0.05. Results At baseline, there was a strong positive correlation between [64Cu]-FAP2287 PET SUVMean and autoradiography (R2 = 0.7806,p < 0.001). No changes in [67Cu]-FAP2287 retention over time was observed following the IMT. [64Cu]-FAP2287 SUVMean proved to be a reliable predictor of survival with 800μCi (R2 = 0.84,p = 0.03) and 1600μCi (R2 = 0.62,p = 0.01). FAP-TRT increased survival compared to controls and IMT. 1600μCi [67Cu]-FAP2287 + IMT significantly decreased tumor volume (p = 0.0003) and increased survival (p = 0.0005) compared to [67Cu]-FAP2287. Conclusion We can noninvasively target and predict response to FAP radiolabeled with elementally paired theranostic probe, [64/67Cu]-FAP2287 in TNBC. IMT synergistically increased response to FAP-TRT and can guide personalized approaches to improve treatment efficacy.

Read PDF

Similar papers

Oct 2026

Integrated [68Ga]Ga-FAPI-7ND PET/CT and stromal profiling of immunocompetent syngeneic tumor models for FAP-targeted radionuclide therapy.

In 4 T1 tumors, [177Lu]Lu-FAPI-7ND showed antitumor activity accompanied by immune microenvironmental alterations, supporting integrated model selection for immunocompetent FAP-RNT studies.

Hui-Jie Li, Yu-Ling Zhang, Xin-Yin Ren et al. · 0 citations
Open access Oct 2026

Preclinical Evaluation of 177Lu-Labeled PSMA and FAP Bispecific Radioligand for Prostate Cancer

Background/Objectives: During prostate cancer progression, downregulation or loss of prostate-specific membrane antigen (PSMA) expression, together with interlesional heterogeneity, may limit the efficacy of PSMA-targeted radioligand therapy. Fibroblast activation protein (FAP), expressed mainly by activated cancer-ass...

R. Xue, Ya-Chao Liu, Xin-Lin Wang et al. · 0 citations
Oct 2026

Design and Biological Evaluation of FAP-Man, a Mannosylated FAP-Targeted Radioglycopeptide for Tumor Imaging and Radionuclide Therapy.

Fibroblast activation protein (FAP) is an attractive target for radiotheranostic development because of its abundant expression in tumor-associated fibroblasts and limited distribution in normal tissues. Here, we developed FAP-Man, a mannosylated FAP-targeted radioglycopeptide based on the FAP-2286 scaffold, to optimiz...

Miao-Miao Song, En-Tao Liu, Rui Cao et al. · 0 citations
Oct 2026

FAP-targeted [177Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer.

This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.

Jia-Hao Xie, Yi-Jin Zou, Da-Zhi Shi et al. · 0 citations
Nov 2026

Nitroimidazole containing cyclicpeptide [68Ga]Ga-ZJUIQB-G002 as a new FAP-targeting radionuclide tracer.

Fibroblast activation protein (FAP) is one of the most extensively studied and promising targets for cancer diagnosis and therapy. Although small-molecule FAP-targeting radiopharmaceuticals are widely used, their clinical utility is often limited by rapid tumor washout and suboptimal therapeutic efficacy. To address th...

Zhi-Tao Guo, Yi-Lin Zeng, Zhen-Feng Liu et al. · 0 citations
Open access Sep 2026

Design and evaluation of a FAP/αvβ3 dual-targeted 68Ga/177Lu heterodimeric radioligand for cancer theranostics

Although the unique features of the tumor microenvironment (TME) present compelling targets for cancer theranostics, monovalent targeting often yields suboptimal outcomes due to heterogeneity and inadequate retention of the theranostic agents. To overcome these limitations, we designed a novel series of heterodim...

Ming-Ming Sun, Dan Feng, Xiang Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.